Regulus, AstraZeneca team up in microRNA preclinical partnership

Regulus Therapeutics will take in $28 million as part of a new partnership with AstraZeneca ($AZN) involving preclinical work on metabolic diseases, cancer and atherosclerosis. Regulus, which focuses on regulating gene expression through microRNAs, will earn equity and an upfront fee as part of the arrangement. As clinical programs advance, AstraZeneca plans to step in to manage them. Regulus, a 2008 Fierce 15 company, has similar deals in place with GlaxoSmithKline ($GSK) and Sanofi ($SNY). Regulus, meanwhile, filed for a $58 million IPO. Story

Suggested Articles

The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.

Evotec will leverage its iPSC know-how with stem cell-based disease modeling to discover novel drugs for retinal diseases.

PureTech affiliate Vedanta Biosciences announced a partnership to create immune-boosting cancer therapies that capitalize on the gut microbiome.